Calciject PMD Solution for Injection

Nazione: Irlanda

Lingua: inglese

Fonte: HPRA (Health Products Regulatory Authority)

Principio attivo:

Calcium gluconate; Magnesium hypophosphite; Dextrose monohydrate; Boric acid

Commercializzato da:

Norbrook Laboratories Limited

Codice ATC:

QA12AA20

INN (Nome Internazionale):

Calcium gluconate; Magnesium hypophosphite; Dextrose monohydrate; Boric acid

Dosaggio:

Not Currently Available

Forma farmaceutica:

Solution for injection

Tipo di ricetta:

LM: Licensed Merchant as defined in relevant national legislation

Gruppo terapeutico:

Sheep

Area terapeutica:

calcium (different salts in combination)

Indicazioni terapeutiche:

Vitamins and minerals

Stato dell'autorizzazione:

Authorised

Data dell'autorizzazione:

1991-10-01

Scheda tecnica

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Calciject PMD Solution for Injection
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
For a full list of excipients, see Section 6.1.
3 PHARMACEUTICAL FORM
Solution for injection.
A clear pale yellow sterile aqueous solution.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Sheep.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Calciject PMD is indicated in the treatment of hypocalcaemia
complicated by a deficiency of magnesium with
accompanying hypoglycaemia.
4.3 CONTRAINDICATIONS
None.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
No special warnings.
Each ml contains:
Active Substance
Calcium Gluconate
166 mg
Boric Acid
34 mg
Dextrose Monohydrate
200 mg
Magnesium Hypophosphite
50 mg
(as hexahydrate)
Excipients
Chlorocresol (as preservative)
1 mg
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_8_
_/_
_0_
_8_
_/_
_2_
_0_
_1_
_4_
_C_
_R_
_N_
_ _
_7_
_0_
_1_
_3_
_8_
_3_
_1_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
The solution should be warmed to body temperature before
administration.
Intravenous injections should be given slowly
and stopped at the first signs of adverse reaction.
Rapid intravenous injection may result in cardiac arrhythmias and, in
severely toxaemic animals, collapse and death.
As intravenous administration of this product could cause death, this
route should only be used by a veterinary surgeon.
SPECIAL